Skip to main content

Table 3 Comparisons of the demographic data and clinical features of patients who met or were beyond the new criteria by imaging and pathology

From: Living donor liver transplantation for hepatocellular carcinoma beyond the Milan criteria: outcome of expanded criteria in tumor size

Demographic and clinical features

Imaging determination

Pathology determination

Size ≤ 6 & < 10 cm (n = 134)

Size > 6 & ≥ 10 cm (n = 21)

p

Size ≤ 6 & < 10 cm (n = 127)

Size > 6 & ≥ 10 cm (n = 28)

p

Mean ± SD

(range)

Mean ± SD

(range)

Mean ± SD

(range)

Mean ± SD

(range)

Male sex, n (%)

107 (79.9)

19 (90.5)

0.369

100 (78.7)

26 (92.9)

0.109

Age (years)

56.18 ± 7.22

(35–73)

56.38 ± 9.71

(35–72)

0.928

56.43 ± 7.51

(35–73)

55.18 ± 7.92

(35–72)

0.429

MELD score

13.07 ± 7.40

(5.0–40.0)

13.95 ± 6.77

(6.0–35)

0.610

13.26 ± 7.45

(5.0–40.0)

12.89 ± 6.67

(6.0–35)

0.881

AFP (ng/mL)

258.80 ± 1008.63 (0.97–7224.41)

9501.08 ± 38,059.54

(4.09–170,961.00)

0.291

214.60 ± 905.04 (0.97–7224.41)

7046.68 ± 321.86.63

(4.09–170,961.00)

0.271

Blood loss (ml)

2779.48 ± 3008.75

(300.0–23,000.0)

3957.14 ± 4393.90 (200.0–16,000.0)

0.248

2874.02 ± 3153.83

(300.0–23,000.0)

3233.93 ± 3646.67 (200.0–16,000.0)

0.596

Max HCC size (cm)

2.25 ± 1.41

(0.0–5.8)

6.51 ± 3.01

(1.6–14.5)

 < 0.001

2.76 ± 1.36

(0.0–6.0)

7.00 ± 3.43

(2.5–16.10)

 < 0.001

Total HCC size (cm)

3.28 ± 2.36

(0.0–9.7)

12.50 ± 4.70

(6.6–25.4)

 < 0.001

4.11 ± 2.55

(0.0–14.00)

12.45 ± 4.87

(6.20–22.8)

 < 0.001

HCC number

1.74 ± 1.65 (0.0–10.0)

4.60 ± 3.44

(1.0–10.0)

0.002

2.16 ± 1.80

(0.0–14.0)

4.29 ± 2.88

(1.0–10.0)

0.001

cHC-CC, n (%)

6 (4.5)

1 (4.8)

1.000

7 (5.5)

0 (0)

0.352

Vascular invasion, n (%)

10 (7.5)

3 (14.3)

0.387

18 (14.2)

6 (21.4)

 < 0.001

AFP > 400 (ng/mL), n (%)

11 (8.2)

7 (33.3)

 < 0.001

9 (7.1)

9 (32.1)

 < 0.001

Recurrent, n (%)

27 (20.1)

11 (52.4)

0.001

22 (17.3)

16 (57.1)

 < 0.001

Mortality, n (%)

32 (23.9)

12 (57.1)

0.002

28 (22.0)

16 (57.1)

 < 0.001

  1. MELD model for end-stage liver disease, AFP alpha-fetoprotein, HCC hepatocellular carcinoma, cHC-CC combined hepatocellular-cholangiocarcinoma